Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb faces a major patent cliff: Eliquis is set to lose patent protection in 2028, which could trigger a sharp revenue decline as generics enter. The article argues BMY is actively offsetting the impact with multiple new drugs (Camzyos, Opdualag, Breyanzi, Reblozyl) and a pipeline described by management as the deepest in a decade, but it still cautions the stock isn’t a short-term buy. While the risk is clear, long-term confidence is tied to successful product replacement rather than a potential AstraZeneca acquisition (seen as unlikely).

Analysis

The market implication is less about the 2028 cliff itself than the gap between visible cash flow today and the earnings reset that will get discounted over the next 12-24 months. For a mature large-cap pharma name, that usually means a capped multiple: every strong quarter buys time, but it does not remove the need for a replacement engine, so the stock can look optically cheap while still being structurally range-bound.

The real winners are not obvious in the headline. Generic manufacturers, payer intermediaries, and any large pharma with cleaner patent runways benefit from capital rotating away from businesses with a known revenue air-pocket. That favors relative value over outright beta: if management can prove the pipeline is more than a slide deck, the stock can squeeze higher, but absent hard clinical or launch data, the burden of proof stays on BMY and the multiple should stay discounted versus peers with fresher growth.

The main tail risk is that pipeline enthusiasm proves non-linear: one or two launch disappointments would force investors to start valuing the company off the post-cliff earnings base months before 2028. Conversely, a credible M&A bid would be the fastest reversal, but mega-merger execution and antitrust scrutiny make that a low-probability, high-volatility path rather than a base case. The contrarian miss is that the stock may already be too rich for a 'wait for the pipeline' story if the market starts pricing in 2028 earlier than bulls expect.

Key Decisions for Investors

• Initiate a relative-value short BMY / long AZN pair on any strength, targeting the next 3-6 months; thesis is that BMY’s known patent decay should compress its multiple versus a cleaner-growth large-cap pharma peer. Risk/reward improves if the spread widens on pipeline disappointment or if the M&A rumor fades.
• If long-only exposure is required, keep BMY as a watchlist name rather than a new core buy until there is hard evidence of post-Eliquis replacement in earnings or guidance; the next falsifier is a pipeline miss or downshift in long-range revenue assumptions.
• Use BMY call overwriting rather than outright long stock if already owned; the setup is more about harvesting yield while waiting for data than expecting a re-rating. This fits a 6-12 month hold where upside is likely capped by the looming earnings reset.
• Monitor for a sector rotation into names with cleaner 2-3 year patent visibility; if that starts, use it to add to the short leg of BMY rather than chase the whole pharma basket.